Lv2
180 积分 2022-07-13 加入
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?
6小时前
待确认
[Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)]
9小时前
已完结
Beyond PD‐L1: Assessment of LAG‐3 and other predictive biomarkers in non–small cell lung carcinoma
2个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
4个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
6个月前
已完结
Abstract CT034: Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
9个月前
已关闭
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
10个月前
已完结
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant
10个月前
已完结
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
10个月前
已完结
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
1年前
已完结
皖公网安备34019202002308
